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ABSTRACT
Objective To study the relationship between spinal 
mobility, radiographic damage of the spine and spinal 
infl ammation as assessed by MRI in patients with 
ankylosing spondylitis (AS).
Methods In this subanalysis of the Ankylosing 
Spondylitis Study for the Evaluation of Recombinant 
Infl iximab Therapy cohort, 214 patients, representing an 
80% random sample, were investigated. Only baseline 
data were used. MRI infl ammation was assessed by the 
AS spinal MRI activity (ASspiMRI-a) score, structural 
damage by the modifi ed Stoke AS Spine Score (mSASSS) 
and spinal mobility by the linear defi nition of the Bath 
Ankylosing Spondylitis Metrology Index (BASMI). 
Univariate correlations were calculated on baseline 
values using Spearman rank correlation. Independent 
associations between the variables of interest were 
investigated by multivariate linear regression analysis. 
Associations with clinical disease activity, C-reactive 
protein, disease duration, age, gender, body mass index 
and HLA-B27 status were also investigated. Subanalyses 
were performed according to disease duration.
Results BASMI correlated moderately well with 
mSASSS (Spearman’s ρ=0.6) and weakly with 
ASspiMRI-a (ρ=0.3). A best-fi t model for BASMI 
included both mSASSS (regression coeffi cient 
(B)=0.865, p<0.001) and ASspiMRI-a (B=0.236, 
p=0.018). In patients with a disease duration ≤3 years, 
B was greater for ASspiMRI-a than for mSASSS (0.595 
vs 0.380), while in patients with a disease duration >3 
years B was greater for mSASSS than for ASspiMRI-a 
(0.924 vs 0.156).
Conclusion Spinal mobility impairment in AS is 
independently determined both by irreversible spinal 
damage and by reversible spinal infl ammation. Spinal 
mobility impairment is more infl uenced by spinal 
infl ammation in early disease, and by structural damage 
in later disease.
INTRODUCTION
Ankylosing spondylitis (AS) is a chronic pro-
gressive inﬂ ammatory disorder characterised by 
inﬂ ammatory back pain. Many axial anatomi-
cal structures may be involved in AS. Sacroiliitis 
may occur as well as spondylitis, spondylodiscitis, 
( spinal) enthesitis and arthritis of the zygoapo-
physeal, costo vertebral and costosternal joints. 
The disease is characterised by bony fusion of the 
axial skeleton, which can be detected best on plain 
radiographs of the spine.1
MRI has emerged in recent years as an assessment 
tool because of its ability to detect inﬂ ammation 
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in the sacroiliac joints, the spine and other joints 
affected by AS.2 3 Only specialised MRI techniques, 
such as the short τ inversion recovery (STIR) tech-
nique, the T2-weighted gradient-echo sequence 
after fat suppression (T2-FS) and the T1-weighted 
turbo spin-echo sequence after administration of 
contrast agent (gadolinium diethylenetriamine-
pentaacetic acid (T1/Gd-DTPA)), can detect inﬂ am-
mation with a high level of speciﬁ city.2 4 Increased 
signal on T2-FS and STIR images reﬂ ect bone mar-
row oedema (BMO), while signal enhancement 
after contrast administration on T1 images reﬂ ects 
hypervascularisation,5 both undetectable with 
conventional radiography.6 7
The association between radiographic damage 
of the spine and spinal mobility impairment in AS 
has been unequivocally demonstrated at the group 
level.8–12 However, at the individual level, the asso-
ciation between spinal mobility and radiographic 
damage is not so strong that spinal mobility can be 
used as a proxy for radiographic evaluation,12 an 
observation that does not dispute the concept that 
radiographic damage is associated with decreased 
spinal mobility. One of the possible explanations 
for the discordance between the level of spinal 
mobility impairment and the degree of radio-
graphic damage (eg, patients with severe impair-
ment despite absent or mild radiographic damage) 
might be that spinal inﬂ ammation contributes to 
spinal mobility impairment in patients with AS. 
This hypothesis is underlined by the observation 
in clinical trials that anti-tumour necrosis factor α 
(TNFα) therapy may increase spinal mobility after 
only a few months of treatment,13–15 which is in 
accordance with the suppression of active spinal 
inﬂ ammation as seen on MRI.16–19
Taking into account the possibility that spinal 
inﬂ ammation may be an important and potentially 
reversible factor determining spinal mobility, the 
aim of this study was to investigate the relation-
ship between spinal mobility, radiographic damage 
of the spine and spinal inﬂ ammation as assessed 
by MRI in patients with AS, taking other possible 




This study is an investigator-performed subanaly-
sis of the ASSERT (Ankylosing Spondylitis Study 
for the Evaluation of Recombinant Inﬂ iximab 
Therapy) cohort.14 In total 214 patients were 
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investigated. Only baseline data were used. These 214 patients 
were part of a representative 80% random sample (224 patients) 
of the ASSERT cohort. Ten patients were excluded from the 
analysis owing to incomplete radiographic assessment (n=7), 
incomplete MRI assessment (n=1) or both (n=2). In brief, 
ASSERT was a double-blind, placebo-controlled clinical trial 
with inﬂ iximab that included patients with AS (according to 
the modiﬁ ed New York criteria20) for at least 3 months before 
screening, with a Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI) score ≥4 (range 0–10), and with a spinal pain 
assessment score ≥4 on a visual analogue scale (range 0–10 cm). 
Patients were excluded from the study if they had total ankylo-
sis of the spine, other inﬂ ammatory rheumatic disease or ﬁ bro-
myalgia. Detailed inclusion and exclusion criteria of patients in 
the ASSERT trial have been described previously.14
Disease severity assessments
Spinal mobility was assessed by the Bath Ankylosing 
Spondylitis Metrology Index (BASMI), a combined index com-
prising ﬁ ve measures of spinal mobility and hip involvement in 
patients with AS. It includes measures of lateral lumbar ﬂ exion, 
tragus-to-wall distance, lumbar ﬂ exion, intermalleolar distance 
and cervical rotation.21 22 The Assessment of SpondyloArthritis 
international Society (ASAS) has adopted the BASMI as one of 
the measures of their core set for spinal mobility assessment in 
AS.23 The recently proposed linear deﬁ nition of the BASMI24 
showed greater sensitivity to change than the BASMI with 3 
and 11 grades and was used in this study; moreover, it is more 
appropriate to statistical analysis. Range is from 0 to 10, with 
higher scores representing greater spinal mobility impairment. 
Disease activity was assessed both by the BASDAI25 and by 
the newly developed ASAS-endorsed Disease Activity Score for 
use in AS, the ASDAS.26 The BASDAI (range 0–10) is a self-
administered, patient-based questionnaire and consists of six 
questions completed on a 10 cm visual analogue scale, related 
to particular symptoms of the disease (fatigue/tiredness, axial 
pain, pain/swelling in joints, pain/discomfort in entheses, stiff-
ness severity and duration). The following ASDAS formula was 
used in this study: (0.121 × back pain) + (0.058 × duration of 
morning stiffness) + (0.110 × patient global) + (0.073 ×  peripheral 
pain/swelling) + (0.579 × ln (C-reactive protein (CRP) + 1)). 
For both the BASDAI and ASDAS, higher scores represent 
higher disease activity.
Radiographic assessment and scoring method
Lateral radiographic views of the cervical and lumbar spine 
were used and scored according to the modiﬁ ed Stoke AS 
Spine Score (mSASSS) scoring system.27 The total mSASSS 
is the sum (range 0–72) of the numerical scores for the ante-
rior corners of the cervical spine from the lower border of 
C2 to the upper border of T1, and the anterior corners of 
the lumbar spine from the lower border of T12 to the upper 
border of S1 (total of 24 corners). Each vertebral corner is 
scored as follows: 0=normal; 1=erosions, sclerosis or squar-
ing; 2=syndesmophytes; 3=bridging syndesmophytes. The 
mSASSS was chosen by ASAS and the international Outcome 
Measurement in Rheumatoid Arthritis Clinical Trials as the 
preferred measure for measuring structural damage and pro-
gression in AS.28 Patients who had more than three vertebral 
corners missing were excluded; if ≤3 corners were missing, the 
mean of the other scoring corners was used for imputation, 
as previously reported.29 Two qualiﬁ ed and well-trained read-
ers who were blinded to the patient’s identity and treatment 
evaluated each radiograph independently. The mean of both 
readers’ scores was used in the analysis.
MRI assessment and scoring method
Images were scored according to the AS spinal MRI activity 
(ASspiMRI-a) score,30 31 a widely used MRI scoring system, 
recently validated in a multi-reader exercise.32 33 With the 
ASspiMRI-a score, activity is assessed at the level of the disco-
vertebral unit (DVU). A DVU is deﬁ ned as the area between two 
virtual horizontal lines through the middle of two adjacent ver-
tebrae. The combined information provided by T1/Gd-DTPA 
and STIR sequences was used for scoring the MR images and 
each DVU was given an MRI activity score based on the amount 
of BMO or erosions, as follows: 0=no abnormalities, 1=minor 
BMO involving ≤25% of the DVU; 2=moderate BMO involving 
>25% but ≤50% of the DVU; 3=major BMO involving >50% 
of the DVU; 4=BMO and minor erosion involving ≤25% of the 
DVU; 5=BMO and moderate erosion involving >25% but ≤50% 
of the DVU; 6=BMO and major erosion involving >50% of the 
DVU. Thus, the ASspiMRI-a score for each DVU ranges from 
0 to 6. Since 23 DVUs are assessed (from C2 to S1), the total 
ASspiMRI-a score for the spine ranges from 0 to 138. In stud-
ies concerning the ASspiMRI-a score, no description has been 
given as to how missing DVU scores should be handled. In this 
study, we chose to exclude patients who had >2 DVU scores 
missing; if ≤2 DVU scores were missing, the mean of the other 
DVU scores was used for imputation. Two qualiﬁ ed and well-
trained readers, different from the readers of the radiographs, 
who were blinded to the patient’s identity and treatment eval-
uated each sequence independently. The mean of both readers’ 
scores was used in the analysis.
Statistical analysis
All data are expressed as median (IQR) or proportion if applica-
ble. Simple univariate correlations were calculated on baseline 
values using Spearman rank correlation. Independent associa-
tions between the variables of interest were investigated by 
linear regression analysis, using BASMI as the dependent vari-
able. The relationship between spinal mobility as measured by 
the BASMI, MRI inﬂ ammation as assessed by the ASspiMRI-a 
score and structural damage according to the mSASSS was ﬁ rst 
investigated. Second, the contributory or confounding effect of 
other independent variables was investigated one by one: dis-
ease activity as assessed by the ASDAS or the BASDAI, CRP, 
disease duration, age, gender, body mass index and HLA-B27 
status. Finally, a best-ﬁ t model with the relevant variables was 
built. Non-normally distributed variables (mSASSS, ASspiMRI-a 
score, CRP and disease duration) underwent a normalisa-
tion procedure using the van der Waerden technique before 
being entered into the linear regression analysis. Interactions 
between mSASSS, ASspiMRI-a, CRP, age, disease duration and 
gender were tested. Because of a relevant statistical interaction 
between disease duration and ASspiMRI-a/mSASSS, a sub-
analysis was performed for patients with low (≤3 years) versus 
high (>3 years) disease duration (the 3-year cut-off point cor-
responding to the ﬁ rst quartile). All the statistical analyses were 
performed using SPSS 16 (SPSS, USA).
RESULTS
Baseline clinical, imaging and demographic characteristics of 
the study population
We analysed data of 214 patients, for whom all baseline variables 
were available. Table 1 shows the baseline clinical, imaging and 
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radiographic damage of the spine (Figure 1B), using the regres-
sion equation obtained from the untransformed data. From the 
graphs, it is clear that both mSASSS and ASspiMRI-a are inde-
pendently determining the value of BASMI.
Owing to a relevant statistical interaction, patients were then 
separated according to disease duration (table 3). In patients 
with a disease duration ≤3 years, B was greater for ASspiMRI-a 
than for mSASSS (0.595 vs 0.380), while in patients with a 
disease duration >3 years, B was greater for mSASSS than for 
ASspiMRI-a (0.924 vs 0.156).
DISCUSSION
The results of this study show that spinal mobility impairment 
in AS is independently determined by irreversible spinal dam-
age as well as by reversible spinal inﬂ ammation. These ﬁ ndings 
are consistent with clinical data reporting the improvement of 
both spinal inﬂ ammation and spinal mobility after treatment 
with anti-TNFα13–15 and with studies conﬁ rming the association 
between radiographic damage of the spine and spinal mobility 
impairment at the group level8–12 but not always at the indi-
vidual level.12 It conﬁ rms that spinal inﬂ ammation may explain 
those cases of discordance between the level of spinal mobility 
impairment and the degree of radiographic damage.
Moreover, the results of this study also show that spinal 
mobility impairment is more inﬂ uenced by spinal inﬂ amma-
tion in early disease, and by structural damage in later disease, 
which may imply that spinal mobility can better be maintained 
by early as compared with delayed intervention.
To our knowledge, only one study has assessed the rela-
tionship between MRI spinal inﬂ ammation and spinal mobil-
ity. Rudwaleit et al34 reported a Spearman r coefﬁ cient of 
0.238 between the Berlin MRI spine score19 and the BASMI. 
This correlation coefﬁ cient was not statistically signiﬁ cant, 
which may be owing to the small sample size of the study 
(46 patients with active AS who participated in randomised 
controlled trials). In the same study, the authors reported that 
the MRI scores of the spine did not correlate at all with other 
disease activity markers, including BASDAI, patient global, 
morning stiffness, CRP and erythrocyte sedimentation rate. 
However, this study also showed that widespread inﬂ amma-
tion in the spine as detected by MRI contributes to predicting 
a major clinical response in patients with active AS treated 
with anti-TNFα agents.
Owing to its ability to detect inﬂ ammatory changes, and in 
light of the paucity of reliable objective measures to quantify 
disease activity in AS, MRI has been increasingly used as a sur-
rogate end point in clinical trials of TNFα-blocking agents. MRI 
has also evolved as an important diagnostic tool in patients 
without deﬁ nite radiographic sacroiliitis, because it visualises 
active (acute) inﬂ ammation in the sacroiliac joints and the spine 
and may therefore be a relevant tool for the early diagnosis of 
axial spondyloarthritis (SpA), including AS.35 36 By showing that 
inﬂ ammatory changes (and not only structural changes) contrib-
ute to spinal mobility impairment, this study gives a new and 
original meaning to MRI spinal inﬂ ammation, further elucidat-
ing its role in the burden of disease.
Most likely, spinal inﬂ ammation prevails in the early phase of 
AS, whereas at later stages, the disease burden is often caused 
both by inﬂ ammatory and secondary changes. Given that anti-
TNFα therapy is highly anti-inﬂ ammatory and effective in the 
long-term suppression of active spinal inﬂ ammation as seen on 
MRI,16–19 the ﬁ nding that spinal mobility impairment is more 
inﬂ uenced by spinal inﬂ ammation in early disease supports the 
demographic characteristics of the study population. The study 
population was typical of patients with moderate-to-severe AS. 
Most patients were men (78.5%) and were HLA-B27 positive 
(89.7%). At baseline, 79.9% of the patients had elevated CRP 
levels (CRP >0.5 mg/dl), 82.2% of the patients had evidence of 
spinal inﬂ ammation (ASspiMRI-a score >0 by any reader) and 
98.6% of the patients had evidence of radiographic damage of 
the spine (mSASSS >0 by any reader).
Relationship between spinal mobility, radiographic damage of 
the spine and spinal infl ammation
BASMI correlated moderately well with mSASSS (Spearman’s 
ρ=0.6, p<0.001) and weakly with ASspiMRI-a (ρ=0.3, p<0.001), 
disease duration (ρ=0.3, p<0.001), CRP (ρ=0.2, p=0.006) and age 
(ρ=0.2, p=0.001). Multivariate linear regression analysis showed 
that the mSASSS and ASspiMRI-a scores were independently 
associated with BASMI (table 2, model 1). We further investigated 
whether the association between spinal mobility, radiographic 
damage of the spine and spinal inﬂ ammation was independent of 
differences in clinical and demographic variables (table 2, models 
2–9). The regression coefﬁ cient (B) for the relationship between 
BASMI and mSASSS (B=0.841; p<0.001) and for the relationship 
between BASMI and ASspiMRI-a (B=0.213; p=0.031) was only 
signiﬁ cantly inﬂ uenced by adding gender to the model (>10% 
change in the value of B). A best-ﬁ t model for BASMI (table 3) 
included mSASSS (B=0.865; p<0.001), ASspiMRI-a (B=0.236; 
p=0.018) and gender (B=−0.305; p=0.165). Results were similar 
if disease duration (almost signiﬁ cant in the exploratory analysis 
shown in table 2) was included in the model: mSASSS (B=0.809; 
p<0.001), ASspiMRI-a (B=0.244; p=0.014), disease duration 
(B=0.171; p=0.065) and gender (B=−0.275; p=0.210). Of note, 
the analysis using the untransformed variables produced similar 
results to the analysis with normalised variables, which adds to 
the robustness of the results (data not shown). Figure 1 plots the 
relationship between spinal mobility and radiographic damage 
of the spine for three different preset values of spinal inﬂ am-
mation (Figure 1A) and the relationship between spinal mobil-
ity and spinal inﬂ ammation for three different preset values of 
Table 1 Summary of the baseline clinical, imaging and demographic 
characteristics of the study population (n=214)*
Characteristics Value
Male (n (%)) 168 (78.5)
Age (years) 40 (32, 46)
Disease duration (years) 9 (3, 16)
BMI (kg/m2) 25.5 (22.6, 27.9)
History of uveitis (n (%)) 135 (63.1)
History of psoriasis (n (%)) 20 (9.3)
History of IBD (n (%)) 15 (7.0)
HLA-B27 positive (n (%))† 191 (89.7)
BASMI 4.6 (3.6, 5.8)
ASDAS 4.0 (3.4, 4.6)
BASDAI 6.5 (5.3, 7.0)
CRP level (mg/dl)‡ 1.5 (0.7, 2.9)
mSASSS 13.8 (4.5, 29.1)
ASspiMRI-a 4.5 (0.5, 9.8)
*Except were indicated otherwise, values are the median (IQR); †one patient was not 
assessed for HLA-B27 status; ‡normal range 0–0.5 mg/dl.
ASDAS, Ankylosing Spondylitis Disease Activity Score; ASspiMRI-a, Ankylosing 
Spondylitis spinal MRI activity; BASDAI, Bath Anklyosing Spondylitis Disease Activity 
Index; BASMI, linear defi nition of the Bath Ankylosing Spondylitis Metrology Index; 
BMI, body mass index; CRP, C-reactive protein; IBD, infl ammatory bowel disease; 
mSASSS, modifi ed Stoke Ankylosing Spondylitis Spine Score.
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concept of a ‘window of opportunity’ to treat patients before 
they develop irreversible bony changes and suggests that early 
treatment of reversible inﬂ ammatory lesions may be of great 
importance in recovering mobility and achieving better patient 
outcomes. The relationship between ankylosis and spinal inﬂ am-
mation is still a matter of debate. In fact, there is now evidence 
that anti-TNFα therapy will not inﬂ uence radiographic progres-
sion in patients with established AS.37 38 Irrespective of this 
relationship, the ﬁ ndings from this study have immediate impli-
cations for patient care and patient outcome, since they show a 
relationship between spinal inﬂ ammation and spinal mobility, 
which, in turn, has direct implications for the function and qual-
ity of life.39 40 Ultimately, the ﬁ ndings from this study may also 
be of relevance to a group of patients with a substantial dis-
ease burden but unmet need: the patients with non-radiographic 
axial SpA,41 for whom the recent publication of validated clas-
siﬁ cation criteria for axial SpA35 36 will facilitate the conduct of 
clinical trials and observational studies. In addition, the ﬁ nding 
that in established disease spinal mobility is mainly explained 
by structural damage indicates that spinal mobility can also be 
seen as a surrogate measure for long-term outcome. The 3-year 
cut-off point used in this study is arbitrary and should not be 
used as a reference value. Moreover, spinal inﬂ ammation can-
not be neglected in later disease as many of these patients have 
signiﬁ cant spinal inﬂ ammation. Furthermore, the beneﬁ t of anti-
TNFα therapy in later disease is indisputable and goes beyond 
the reduction of spinal inﬂ ammation and improvement of spinal 
mobility.
Some limiting factors should be taken into account. One of 
them may be the fact that mSASSS only accounts for struc-
tural damage in the anterior corners of the cervical and  lumbar 
spine. Exclusion of the thoracic spine and of the posterior sites 
of the spine may result in an underestimation of the struc-
tural damage, as may the exclusion of the vertebral ligaments 
and facet joints, which also have an important role in spinal 
mobility. This study, however, gives justice to the hypothe-
sis that involvement of the structures not measured directly 
by mSASSS is in line with structures measured by mSASSS. 
Another limiting factor may be the fact that the ASspiMRI-a 
score only captures spinal inﬂ ammatory activity (bone oedema 
and discitis) at the DVU level, excluding the surrounding 













 B 0.865 0.380 0.924
 95% CI 0.677–1.054 −0.099 to 0.858 0.715–1.134
 p Value <0.001 0.117 <0.001
ASspiMRI-a
 B 0.236 0.595 0.156
 95% CI 0.041–0.432 0.173–1.016 −0.070 to 0.383
 p Value 0.018 0.007 0.174
Gender (male)
 B −0.305 −0.454 −0.299
 95% CI −0.738 to 0.127 −1.338 to 0.429 −0.796 to 0.198
 p Value 0.165 0.307 0.237
Results are shown for the entire AS population and according to disease duration.
ASspiMRI-a, Ankylosing Spondylitis spinal MRI activity; B, regression coeffi cient; 
BASMI, linear defi nition of the Bath Ankylosing Spondylitis Metrology Index; mSASSS, 
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soft tissues and facet joints, which may underestimate 
 inﬂ ammatory activity. However, none of the other available 
scoring methods for structural damage or spinal inﬂ amma-
tion performs better than the mSASSS and ASspiMRI-a,29 32 
respectively, and it is unlikely that this can inﬂ uence the over-
all conclusions of this study, although at the individual level 
it may be of some importance. The above arguments would 
be mainly of importance if we did not establish a relationship. 
Another  theoretical limitation pertains to lack of generalisabi-
lity, or that the results of this study are only valid within the 
ASSERT population. However, we do not believe that external 
validity is compromised because the population includes the 
entire range of spinal mobility impairment, radiographic dam-
age and spinal inﬂ ammation.
In summary, this study suggests that both the assessment of 
MRI spinal inﬂ ammation and radiographic damage of the spine 
have an independent and additive value in the outcome mea-
surement of AS, both contributing to spinal mobility impair-
ment. This study also suggest that spinal mobility impairment 
is more inﬂ uenced by spinal inﬂ ammation in early disease, and 
by structural damage in later disease, which may imply that spi-
nal mobility can better be maintained by early rather than late 
intervention.
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Figure 1 (A) Relationship between spinal mobility and radiographic 
damage of the spine for three different preset values of spinal 
infl ammation; (B) relationship between spinal mobility and spinal 
infl ammation for three different preset values of radiographic damage 
of the spine. An increase of 10 units in mSASSS (range 0–72) leads to 
an increase of 0.46 in BASMI (range 0–10) independent of the effect 
of ASspiMRI-a; similarly, an increase of 10 units in ASspiMRI-a (range 
0–138) leads to an increase of 0.33 in BASMI. ASspiMRI-a, ankylosing 
spondylitis spinal MRI activity; BASMI, linear defi nition of the Bath 
Ankylosing Spondylitis Metrology Index; mSASSS, modifi ed Stoke 
Ankylosing Spondylitis Spine Score.
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